Okyo Pharma Aktie - OKYO

Professionelle Tools für Privatanleger.

Premium

Current Price

91,00

Gebot

1,20

Fragen

1,60

Volumen

0,00

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

91,00

Handelsbeginn

Letzte Trade

(O)

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain LONDON and NEW YORK, March 10, 2025 (GLOBE...

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma Announces Chairman and CEO Acquire Shares LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO...

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter LONDON and NEW YORK, Jan. 29, 2025 (GLOBE...

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:...

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma...

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE...

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain OK-101 is the first drug candidate to...

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain Neuropathic corneal pain (NCP) is listed in...

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

OKYO - Frequently Asked Questions (FAQ)

What is the current Okyo Pharma share price?

The current share price of Okyo Pharma is 91,00p

What is the 1 year trading range for Okyo Pharma share price?

Okyo Pharma has traded in the range of 0,00p to 0,00p during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
TANTanfield Group Plc	3,20p (25,00%)	67,84k
SENXSerinus Energy Plc	3,25p (25,00%)	2,51M
CLONClontarf Energy Plc	0,0425p (23,19%)	960,85M
THRUThruvision Group Plc	2,20p (22,22%)	9,35M
GSTGstechnologies Ltd	1,825p (17,74%)	56,11M
WSBNWishbone Gold Plc	0,0975p (-46,28%)	167,92M
TUNTungsten West Plc	3,75p (-25,00%)	3,31M
CELCeladon Pharmaceuticals Plc	11,00p (-21,43%)	926,35k
PRDPredator Oil & Gas Holdings Plc	2,90p (-17,14%)	8,69M
VELAVela Technologies Plc	0,0025p (-16,67%)	925,59M
PREMPremier African Minerals Limited	0,01275p (9,44%)	1,06B
CLONClontarf Energy Plc	0,0425p (23,19%)	960,85M
VELAVela Technologies Plc	0,0025p (-16,67%)	925,59M
TRPTower Resources Plc	0,0275p (-5,17%)	454,78M
MSMNMosman Oil And Gas Limited	0,0295p (15,69%)	316,75M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Okyo Pharma Limited (OKYO)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

OKYO Neueste Nachrichten

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Okyo Pharma Limited (OKYO) Börsenkurse

Okyo Pharma Limited (OKYO)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

OKYO Neueste Nachrichten

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE